. Author manuscript; available in PMC: 2017 Jul 1.

Published in final edited form as: Clin Microbiol Infect. 2016 Apr 25;22(7):645.e1–645.e8. doi: 10.1016/j.cmi.2016.04.013

Table 2.

Antimicrobial susceptibility profiles of MRSA colonizing isolates recovered from neonates, N=250

	% Susceptible
Isolate Characteristics	CLI^a	ERY	SXT	RIF	TET	CIP	MUP	CHG
Overall	33	5	99	99	99	42	96	97
Mupirocin
Resistant (N=11)	18	0	100	100	100	9^c	N/A	100
Susceptible (N=239)	34	5	99	99	99	43	N/A	97
Chlorhexidine
Resistant (N=8)	38	0	100	88^d	100	63	100	N/A
Susceptible (N=242)	33	5	99	99	99	41	95	N/A
SCCmec type^b
HA-MRSA (N=120)	1^d	0^d	100	99	100	12^d	93^c	99^c
CA-MRSA (N=129)	62	9	99	99	99	69	98	95

Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; CLI, clindamycin; ERY, erythromycin; SXT, trimethoprim-sulfamethoxazole; RIF, rifampin; TET, tetracycline; CIP, ciprofloxacin; MUP, mupirocin; CHG, chlorhexidine; SCCmec, staphylococcal cassette chromosome mec; HA-MRSA, healthcare-associated MRSA; CA-MRSA, community-associated MRSA.

Note: All isolates were susceptible to linezolid and ceftaroline.

Clindamycin-susceptible isolates that were D-test positive (n=43) were considered clindamycin resistant.

HA-MRSA include SCCmec type II; CA-MRSA includes SCCmec types IV and V; 1 isolate was not typable by SCCmec testing (N=249).

p<0.05.

p≤0.001.